Abstract
ABSTRACT IDEALLY, coronary heart disease should be prevented before it becomes clinically manifest, but when primary prevention fails, prevention of death and recurrent myocardial infarction after the first event, or secondary prevention, is still a worthwhile and achievable goal. Therefore, a review of the results of recent clinical trials on both secondary and primary prevention of coronary heart disease, and of their implications for clinical practice, would seem to be timely and useful.SECONDARY PREVENTION OF CORONARY HEART DISEASE A previous history of myocardial infarction is a recognized risk factor for recurrent events, including sudden death. This review reports on recent clinical trials on the efficacy of platelet-active drugs, β-adrenergic blockers, and lowering blood cholesterol regimen in treatment of this high-risk group of patients. Only selected examples of large-scale clinical trials, both short and long term, are addressed.Clinical Trials on the Protective Effect of Platelet-Active Drugs Platelet-active drugs, such as
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
